

1 **Accuracy and performance of the WHO 2015 and WHO 2019 HIV testing strategies**
2 **across epidemic settings**

3 *Short title: Accuracy and performance of WHO recommended HIV testing strategies*

4 Jeffrey W Eaton^{1§}, Anita Sands², Magdalena Barr-DiChiara³, Muhammad S Jamil³, Rachel
5 Baggaley³, Beth A Tippett Barr⁴, Thokozani Kalua⁵, Andreas Jahn^{5,6}, Mathieu Maheu-Giroux⁷,
6 Cheryl C Johnson³

7 ¹ MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial
8 College London, United Kingdom

9 ² Regulation and Prequalification Department, World Health Organization, Geneva,
10 Switzerland

11 ³ Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva,
12 Switzerland

13 ⁴ US Centers for Disease Control and Prevention, Kisumu, Kenya

14 ⁵ Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi

15 ⁶ International Training and Education Center for Health, Department of Global Health,
16 University of Washington, Seattle, USA

17 ⁷ Department of Epidemiology, Biostatistics, and Occupational Health, School of Population
18 and Global Health, McGill University, Montreal, Canada

19

20 § Corresponding author: Jeffrey W Eaton

21 E-mail addresses of authors:

22 JWE: jeffrey.eaton@imperial.ac.uk

23 AS: sandsa@who.int

24 MBD: barrdichiam@who.int

25 MJ: mjamil@who.int

26 RB: baggaley@who.int

27 BTB: btippettbarr@cdc.gov

28 TK: thokokalua@gmail.com

29 AJ: ajahn@itech-malawi.org

30 MMG: mathieu.maheu-giroux@mcgill.ca

31 CCJ: johnsonc@who.int

32

33 Keywords: HIV diagnosis; testing strategy, testing algorithm, predictive values, accuracy

34 Word count: 3830 words

35 Abstract: 316 words

36 **Abstract**

37 *Background:* WHO 2019 HIV testing guidelines recommended a standard HIV testing strategy
38 consisting of three consecutively HIV-reactive test results on serology assays to diagnose HIV
39 infection. National HIV programmes in high prevalence settings currently using the strategy
40 consisting of only two consecutive HIV-reactive tests should consider when to implement the
41 new guideline recommendations.

42 *Methods and Findings:* We implemented a probability model to simulate outcomes of WHO
43 2019 and the two strategies recommended by WHO 2015 guidelines on HIV testing services.
44 Each assay in the strategy was assumed independently 99% sensitivity and 98% specificity, the
45 minimal thresholds required for WHO prequalification. For each strategy and positivity ranging
46 20% to 0.2%, we calculated the number of false-negative, false-positive, and inconclusive
47 results; positive and negative predictive value (PPV, NPV); number of each assay used, and
48 testing programme costs. We found that the NPV was above 99.9% for all scenarios modelled.
49 Under the WHO 2015 two-test strategy, the PPV was below the 99% target threshold when
50 positivity fell below 5%. For the WHO 2019 strategy, the PPV was above 99% for all positivity
51 levels. The number reported 'inconclusive' was higher under the WHO 2019 strategy.
52 Implementing the WHO 2019 testing strategy in Malawi, would require around 89,000 A3 tests
53 in 2021, compared to 175,000 A2 tests and over 4.5 million A1 tests per year. The incremental
54 cost of the WHO 2019 strategy was less than 2% in 2021 and declined to 0.9% in 2025.

55 *Conclusions:* As positivity among persons testing for HIV reduces below 5% in nearly all
56 settings, implementation of the WHO 2019 testing strategy will ensure that positive predictive
57 value remains above the 99% target threshold, averting misdiagnoses and ART initiations
58 among HIV uninfected people. The incremental cost of implementing the WHO 2019 HIV testing

59 strategy compared to the two-test strategy is negligible because the third assay accounts for a
60 small and diminishing share of total HIV tests.

61 **Introduction**

62 Providing accurate, timely, and affordable HIV diagnosis at the point of care is a critical first step
63 towards delivering HIV treatment and prevention services. To establish HIV diagnosis, the
64 World Health Organization (WHO) recommends HIV testing strategies using multiple HIV
65 serology assays including rapid diagnostic tests (RDTs) and enzyme-immunoassays (EIAs)
66 [1,2]. Each assay should have a sensitivity of greater than or equal to 99% (the assay is reactive
67 for at least 99 out of 100 truly HIV positive specimens) and specificity of greater than or equal to
68 98% (the assay is non-reactive for at least 98 out of 100 truly HIV negative specimens), the
69 minimum thresholds for approval through the WHO prequalification procedure [3,4].

70 To ensure accurate diagnosis in all settings, WHO has previously recommended differentiated
71 HIV testing strategies according to the prevalence of HIV in the population being tested [2,4]. In
72 'high' HIV prevalence populations with prevalence above 5%, two consecutively HIV-reactive
73 test results were recommended to diagnose HIV; when prevalence was below 5%, three
74 consecutively HIV-reactive test results were recommended. This threshold at 5% was
75 established to ensure that the combination of assays utilized in a testing strategy have at least
76 99% positive predictive value (PPV)—that is at least 99 out of every 100 individuals classified as
77 HIV positive are truly HIV positive, or fewer than 1 false-positive per 100 HIV positive individuals
78 tested— when assays attain the minimum 98% specificity requirement [4].

79 When choosing a testing strategy, HIV programmes have typically used national HIV population
80 prevalence (greater or less than 5%) as a proxy to guide whether to implement a 'two-test' or
81 'three-test' strategy. However, as awareness of HIV status has reached high levels, positivity
82 amongst persons presenting for HIV testing services (HTS) has declined steeply in recent
83 years. Even in the highest HIV prevalence settings in southern and eastern Africa, the positivity
84 is below the 5% threshold and expected to further decline in future given high ART coverage

85 and estimated low HIV incidence [5]. A 2018 policy review found that only 25% of national HIV
86 testing guidelines were fully adherent with WHO recommendations on HIV testing strategies [6].
87 Despite declining HIV positivity, few programmes have transitioned from using two HIV-reactive
88 test results to three HIV-reactive test results to maintain high PPV.

89 Responsive to declining positivity and the challenges implementing differentiated guideline
90 recommendations, the 2019 revision of the *WHO Consolidated Guidelines on HIV Testing*
91 *Services* recommended a single ‘standard’ HIV testing strategy for all settings in which HIV
92 testing is conducted. The WHO 2019 testing strategy recommended HIV-reactive results from
93 three consecutive serology assays and simplified the steps for adjudicating cases with
94 discrepant results on serially conducted tests (Figure 1). National HIV programmes should now
95 consider when and how to implement new recommendations to transition from a ‘two-test’ to the
96 ‘three-test’ testing strategy, including the potential implications for accuracy and misdiagnosis,
97 and programme and commodities costs.

98 To support decision making, we analysed the performance of the WHO 2019 standard HIV
99 testing strategy compared to the previous two-test and three-test testing strategies with respect
100 to PPV, negative predictive value (NPV), and the number of HIV-inconclusive results returned at
101 a range of HIV positivity values. Second, we calculated cost and commodity considerations of
102 the respective testing strategies using epidemiologic and HIV testing programme data from
103 Malawi as an example case study.

104 **Methods**

105 *Model*

106 We implemented a probability model to deterministically simulate the expected outcomes of the
107 WHO 2019 HTS Guidelines and the two testing strategies recommended by WHO 2015 HTS

108 Guidelines, including stipulated repetition of one or more assays in the case of discrepant test
109 results (Figure 1) [4,7]. We refer to the ‘high’ and ‘low’ prevalence testing strategies as the ‘two-
110 test’ and ‘three-test’ strategies, respectively. The numbers refer to the sequential assays
111 required for an HIV-positive diagnosis, and not the overall number of assays needed in the
112 respective strategy, as the two-test testing strategy also requires a third assay to be available in
113 the event of discrepant results (Figure 1A) [4].

114 Each assay in the testing strategy was assumed to be independent and perform with 99%
115 sensitivity and 98% specificity, the minimum performance requirements for WHO
116 prequalification [7,8]. WHO recommends that any initially discrepant A1+/A2- cases be
117 repeated immediately using assay 1 (A1). We assumed that repetition of A1 will resolve the
118 discrepancy in 80% of cases (e.g. with presumed ‘use error’ or other random error resulting in
119 initially discrepant results), while the A1+/A2-/A1+ discrepancy persisted 20% of the time (due
120 to false reactivity for A1+ for truly HIV negative persons or low antibody levels not detected with
121 A2 for truly HIV positive persons). Cases that were twice discrepant (initial: A1+ / A2-; repeat:
122 A1+ / A2-) under the WHO 2015 three-test testing strategy were classified as ‘HIV negative’.
123 (This outcome does not occur under the WHO 2019 strategy because A2 is not repeated. Such
124 cases A1+ / A2- / A1+ are reported HIV-inconclusive after repeat A1+ and recommended to
125 retest after 14 days).

126 Input parameters to the model were: (1) Number individuals tested for HIV, (2) proportion truly
127 HIV positive among those tested, (3) WHO HIV testing strategy (two-test or three-test), (4)
128 sensitivity of each assay (assumed 99%), (5) specificity of each assay (assumed 98%), (6)
129 probability that repetition of false-reactive A1 (A1+ for a truly HIV-negative person) is non-
130 reactive upon repetition of A1 (assumed 80%), and (7) HIV testing costs (including commodities,
131 site overheads, staff salaries, and other).

132 *Outputs and cost analysis*

133 The model produced the following outcomes: the absolute number of individuals ruled HIV-
134 positive, HIV-negative, and HIV-inconclusive (who are asked to return after 14 days to undergo
135 testing again), observed HIV-positivity amongst individuals presenting for HTS, number false-
136 positive and number false-negative diagnoses, positive and negative predictive values, number
137 of A1, A2, and A3 products utilized, and estimated total HIV testing costs.

138 Costs were indicative of current HTS programme costs in many low- and middle-income (LMIC)
139 settings and were 'fully loaded' costs including consumables, staff, facilities, and programme
140 management. We assumed an average service delivery cost of US\$2.00 per client tested plus
141 the unit cost of each assay used in the algorithm. The unit cost reported in the WHO Global
142 Price Reporting for a typical product used as A1 was around \$0.80 per test compared to around
143 \$1.60 for a typical product used as A2 [9]. Supply chain monitoring data from Malawi indicate
144 that around 95% of A1 consumables are used for client testing with the remaining 5% for other
145 purposes such as quality assurance, proficiency testing, and loss. For A2 products, used only
146 after an HIV-reactive A1 result, around 70% are used for client testing and 30% for other
147 purposes [10]. Accounting for these factors and other per-test consumables and staff
148 expenditures, we assumed US\$1.30 for each A1 utilized, \$2.30 for each A2 utilized, and
149 US\$2.50 per A3 utilized. Taken together, the cost was around \$3.50 per HIV-negative client
150 tested and \$5.60 to \$8.10 per HIV-positive person tested. For cases initially reported as 'HIV-
151 inconclusive', we accounted for testing commodities and cost for retesting after 14 days, but did
152 not count the HIV status reported at repeat testing in calculations for number classified positive,
153 negative, PPV, or NPV because the primary objective of the HIV testing strategy is to return the
154 accurate HIV testing result at the clinical encounter.

155 *Analyses*

156 We conducted two analyses. First, we simulated the expected HIV testing outcomes per
157 100,000 individuals tested using either the WHO 2019, WHO 2015 two-test or WHO 2015 three-
158 test strategies for true positivity ranging from 20% to 0.2%. We assessed (1) whether each test
159 strategy achieved above the 99% threshold for PPV and NPV when assuming assays
160 performed at the minimum level required for WHO prequalification, (2) the number of HIV-
161 inconclusive results returned, and (3) the number of tests and total HTS cost.

162 Secondly, we used HIV epidemic estimates and projections and HIV testing programme data
163 from Malawi to understand the consequences of changes in HIV testing scale and positivity over
164 time on expected HIV testing programme outcomes.

165 We used 2020 national HIV estimates for Malawi submitted to UNAIDS to extract estimates for
166 the adult (15+) population over the period 2000 to 2025 for the indicators: number of people
167 living with HIV (PLHIV), number aware of HIV status and number on ART, and number of HIV
168 tests conducted, number of persons testing positive for HIV, and number persons diagnosed
169 HIV positive for the first time. Estimates and projections for the number of PLHIV and number
170 on ART were estimated by the Malawi national HIV estimates working group using the
171 Spectrum and EPP models [11,12]. HIV testing programme outcomes over the period 2000 to
172 2019 were estimated from household survey and HIV testing programme data input to the
173 Shiny90 model [13]. Projections for the period 2020 through 2025 assumed that the 2019 rates
174 of HIV testing by age, sex, HIV status, and ART status would continue into the future. We input
175 the estimates for the annual number of tests conducted by HIV status into the HIV testing
176 strategy model to estimate the expected HIV testing programme outcomes had the two-test or
177 WHO 2019 testing strategy been used, and assuming assay performance at the minimum level
178 to attain WHO prequalification.

179 The Malawi HIV testing programme has implemented the high prevalence (two-test) testing
180 strategy for HIV diagnosis, but the simulated results do not represent actual HIV testing
181 programme outcomes for Malawi in at least two ways. Firstly, HIV testing programme data from
182 Malawi suggest improving accuracy over time following a programme of training and quality
183 assurance. Secondly, since 2011 Malawi has implemented retesting for verification of HIV
184 status of all HIV-positive persons before ART initiation [14], which is not included in our
185 simulation.

186 **Results**

187 *Outcomes per 100,000 tested for range of HIV testing positivity*

188 Table 1 summarizes model outcomes per 100,000 persons tested at 10%, 5%, 1%, and 0.5%
189 true positivity amongst persons tested for HIV. The expected number of false-positive
190 classifications is substantially lower with the three-test and WHO 2019 testing strategies at
191 fewer than 1 false HIV-positive per 100,000 individuals tested compared to around 45 false-
192 positives per 100,000 individuals tested with the two-test strategy and does not vary
193 substantially with positivity (Table 1, Figure 2A). In contrast, the expected number of false-
194 negative classifications was proportional to the positivity from 100 false-negatives per 100,000
195 individuals tested at 10% positivity to 10 false-negative per 100,000 individuals tested at 1%
196 positivity with the two-test strategy. The three-test or WHO 2019 testing strategy does not affect
197 the expected number of false-negative classifications.

198 The negative predictive value (NPV) was 99.9% or greater for all testing strategies at all
199 positivity levels, well above the 99% threshold (Table 1, Figure 2B). Under the two-test strategy,
200 the PPV was above the 99% threshold when positivity amongst individuals being tested was
201 above 5%, but declined rapidly as positivity decreased (Table 1, Figure 2B). At 1% positivity, the
202 PPV was 95% under the two-test strategy and this decreased to 91% at 0.5% positivity and

203 81% at 0.2% positivity. With the three-test or WHO 2019 testing strategy, the PPV increased to
204 99.9% at 1% positivity and was well above the 99% threshold for all simulated levels of
205 positivity.

206 The number of results reported as 'HIV-inconclusive', in which the client would be asked to
207 return for retesting after 14 days, was substantially higher under the WHO 2019 testing strategy
208 than either the three-test or two-test strategy. For example, using the WHO 2019 testing
209 strategy at 5% positivity, there were 508 (0.51%) HIV-inconclusive results per 100,000
210 individuals tested, compared to 124 per 100,000 (0.12%) for the three-test strategy and 47.2
211 (0.05%) with the two-test strategy. The increased number reported as HIV-inconclusive through
212 the WHO 2019 testing strategy arose from two sources (Table 2). The majority arose when A1+
213 and A2- were discrepant, and the repeat A1 was HIV-reactive, which was reported as HIV-
214 inconclusive under the WHO 2019 testing strategy. Under the WHO 2015 testing strategies, A2
215 was repeated and would result in either proceeding to A3 or reporting HIV-negative. Secondly,
216 under the WHO 2019 testing strategy, cases that were reactive on each of the first two assays
217 (A1+/A2+), then non-reactive on the third (A3-) were reported HIV-inconclusive. Under the two-
218 test strategy, such individuals were reported HIV positive following A1+/A2+, and when positivity
219 is below 5% the majority are false-positive misclassifications and are actually true negatives
220 (Table 2).

221 *HIV testing commodities and programme costs*

222 The number of A1 used per 100,000 tested was relatively similar and accounted for the majority
223 of tests used for all positivity levels because most clients are classified HIV-negative following
224 A1 and do not undergo further testing (Table 1, Figure 3A). The number of A2 required was the
225 same under the three-test and two-test strategies and increased with positivity. The number of
226 A2 was lower under the WHO 2019 testing strategy because A2 is not repeated following

227 discrepant A1 and A2 results, which accounts for a substantial fraction of A2 usage under the
228 WHO 2015 testing strategies when positivity is low. The number of A3 required was much
229 greater for the three-test and WHO 2019 testing strategies, but even under these two testing
230 strategy the number of A2 required were much larger than A3. This was because a substantial
231 share of A2 are utilized on persons with discrepant A1+/A2– results, which are ultimately
232 classified HIV-negative and do not progress on to A3. The difference in consumption between
233 A2 and A3 increases as positivity declines.

234 At 10% positivity, the total cost for the WHO 2019 testing strategy was 6% higher than the two-
235 test strategy (Table 1; Figure 2C). The cost difference reduced considerably with declining
236 positivity due to the lower consumption of A2 and A3. For testing positivity below 1.5%, the cost
237 for the WHO 2019 testing strategy was slightly lower than the cost for two-test strategy because
238 the reduced need for A2 outweighed the slight increase in A3 consumption.

239 *Estimated and projected changes in HTS outcomes: Malawi example*

240 Figure 4 summarizes estimates and projections for the number of adult PLHIV over the period
241 2000 through 2025 in Malawi. The total adult PLHIV was projected to increase slightly through
242 2025 as PLHIV survive longer on ART. However, the proportion of undiagnosed PLHIV declined
243 rapidly from an estimated 79% in 2005 to 33%, 10% and 5% in 2010, 2019 and 2025,
244 respectively (Figure 4A). Consequently, despite large increases in the number tested for HIV
245 each year, the number of HIV diagnoses peaked in 2010 and is projected to continue to decline
246 (Figure 4B). This was reflected in rapidly declining positivity amongst clients tested. Before
247 2010, positivity in the testing program exceeded the population prevalence as symptomatic
248 PLHIV were more likely to present for testing (Figure 4C). But in 2019, the positivity of
249 individuals being tested for HIV declined to around 3.1% compared to adult HIV prevalence of
250 9.5% and the positivity was projected to further decline in 2025 to 1.2% compared to 8.3%

251 prevalence. The proportion of individuals diagnosed for the first time among all tested for HIV
252 was 1.2% in 2019, declining to 0.5% in 2025.

253 The consequences of declining positivity for expected HIV testing programme quality and costs
254 are consistent with those reported in Table 1 and Figure 2. The expected NPV is substantially
255 above the 99% threshold at all times (Figure 5A). However, the PPV dropped below the 99%
256 threshold in 2018 with the WHO 2015 two-test strategy and will decline to 97% in 2025 if each
257 assay performs at the minimum threshold required for WHO prequalification (Figure 5A). This
258 equates to expecting an average of around 1800 false positive diagnoses per year. In contrast,
259 the PPV remained above 99.9% with the WHO 2019 testing strategy—fewer than 40 false
260 positive diagnoses per year. If the rates of HIV testing are maintained at current levels, an
261 estimated 89,000 tests of A3 would be required to implement the WHO 2019 testing strategy in
262 2021, declining to 64,000 in 2025, compared to around 175,000 tests of A2 and over 4.5 million
263 tests of A1 in 2021 (Figure 5B). The incremental cost of the WHO 2019 testing strategy was
264 less than 2% in 2021, and declined to around 0.9% in 2025 (Figure 5C).

265 **Discussion**

266 Positivity in testing programs has declined below 5% even in countries with high HIV population
267 prevalence [5]. The 2019 WHO HIV testing strategy requires reactive results on three serially
268 conducted serology assays to diagnose HIV infection. This algorithm substantially reduced the
269 number of false-positive misdiagnoses at all levels of positivity in HIV testing programs. When
270 HIV assays perform at the minimum WHO pre-qualification threshold of 98% specificity, the
271 2019 WHO HIV testing strategy ensured that fewer than 1 in 100 persons diagnosed with HIV
272 were false-positive, which was not the case for the two-test strategy used by many high
273 prevalence countries.

274 The number of false-negative misdiagnoses reduced proportionally as positivity declined for HIV
275 under all three testing strategies. The WHO 2019 testing strategy also increased the expected
276 number of HIV-inconclusive results returned, for example from 0.04% under the two-test
277 strategy to 0.45% with the WHO 2019 testing strategy at 1% positivity. However, at low positivity
278 levels, increased HIV-inconclusive results arose primarily due to simplification of testing strategy
279 for persons who are initially discrepant, reducing opportunity for errors, and among individuals
280 who are truly HIV negative but would have been misclassified as HIV-positive under the two-test
281 strategy. Had those HIV-inconclusive individuals received a false-positive misdiagnosis under
282 the two-test testing strategy, the cost of misdiagnosis and life-long treatment would be
283 significant [14,15].

284 The two-test and three-test testing strategies both require an A3 to be available, but the number
285 of A3 consumed is expectedly much greater with the 3-test strategy since it is deployed for all
286 individuals with reactive results for both A1 and A2 rather than only for those with discrepant
287 test results (i.e. A1 reactive but A2 non-reactive). However, the number A3 required remains
288 lower than A2 and the difference increases as positivity declines. This is because at low
289 positivity, a large number of A2 are utilized for discrepant A1+/A2- results, which are classified
290 as HIV negative by repeating A1 and do not proceed to A3.

291 Declining positivity amongst individuals who undergo HIV testing is a reflection of successful
292 scale-up and implementation of HIV programmes that have reduced the undiagnosed HIV
293 population [5]. Our case study of Malawi exemplifies the consequences for the HIV testing
294 program. While HIV population prevalence has declined slowly from 11% in 2005 to 9.5% in
295 2019, the positivity amongst individuals undergoing HIV testing fell steeply from 15% to 3% over
296 the same period. Assuming 98% specificity for each assay used, the 2015 WHO two-test testing
297 strategy (designed for 'high prevalence' settings) was expected to perform below 99% PPV
298 since 2018 in Malawi and a further decline in PPV was projected. To mitigate this, Malawi has

299 pioneered quality testing initiatives, including verification testing (using the same two-test testing
300 strategy in parallel) before ART initiation. Malawi service delivery data suggests steady
301 improvements in testing accuracy which are reflected in a declining proportion of inconclusive
302 results and discrepant verification testing results. While the true number of false-positive and
303 false-negative misdiagnosis is unknown in Malawi, the simulated results illustrate the
304 importance to consider the 2019 WHO testing strategy.

305 The incremental cost of switching to the WHO 2019 testing strategy was less than 2% of the
306 total HIV testing programme cost and will decline further in the future. The low and decreasing
307 incremental cost is because the large majority of HIV testing clients are HIV negative and do not
308 proceed past A1, which thus accounts for the largest share of HTS programme cost despite a
309 lower unit cost. Our analysis assumed that the incremental cost of switching to the WHO 2019
310 testing strategy was captured by the additional cost of delivering A3. However, in many settings
311 A3 is not routinely stocked at all testing locations and specimens with discrepant test results are
312 instead referred to laboratories for additional testing to confirm their HIV status. Additional
313 training and supply chain costs of switching to a three-test strategy in such settings are
314 uncertain. Incorporating a new A3 into the testing strategy would require training of all HTS
315 providers, but such training activities could be conducted routinely as part of programme
316 management, quality assurance, and implementation of other guideline changes. Resolving
317 more cases at the facility instead of requiring discrepant specimens to be sent to a laboratory
318 should also offset costs of transport, information management, and tracing clients to provide
319 results. We were not able to estimate the cost for this additional lab testing using the current
320 policy, but considerable delays in returning such results from the reference lab have highlighted
321 the challenges with this approach. Timing changes and shifts in the testing strategy alongside
322 other changes in updates to guidelines, log-books and integrated trainings can also increase
323 cost efficiencies.

324 Consistent with WHO guidelines, we assumed that all tests in the algorithm were conducted
325 serially, except for the parallel replication of A1 and A2 following initial discrepant A1+/A2-. An
326 HIV diagnosis with the WHO 2019 testing strategy would require three finger pricks for clients
327 with a reactive A1. There has been some consideration to conducting A2 and A3 in parallel
328 could reduce the additional finger prick. However, this could also lead to additional challenges
329 with the interpretation of discrepant test results and add substantial wastage of A3 since, as
330 positivity becomes lower, an increasing share of those progressing to A2 were false reactive to
331 A1 and classified as HIV negative on A1 repetition, and not progress to A3. For example, in
332 Malawi, parallel application of A2 and A3 would roughly double the number of A3 required.

333 There were two assumptions with limited empirical data to which our findings are potentially
334 sensitive: (1) that 80% of discrepant A1+/A2- would be correctly resolved upon replication of
335 the A1 and A2, while 20% would remain discrepant, and (2) that each assay in the testing
336 strategy is independent and performs at the minimum threshold for WHO prequalification,
337 namely 98% specificity. Our conclusions should be interpreted considering these limitations and
338 should be reevaluated as more evidence on these points becomes available.

339 Our modelling suggests that transitioning to the WHO 2019 HIV testing strategy, requiring three
340 reactive tests to diagnose HIV, ensures accuracy and quality of HIV diagnosis into the future
341 with minimal consequences for overall HIV testing programme costs. The alternative, without
342 adopting the strategy requiring three reactive tests to diagnose HIV, is increasing false positive
343 misdiagnoses as a proportion of all those newly diagnosed with HIV. This incurs unnecessary
344 lifelong ART costs for HIV negative persons [14,15], unquantified individual physical,
345 psychosocial and emotional harms of receiving a false positive HIV misdiagnosis [16,17], and
346 undermining confidence in the health system. While the WHO 2019 HIV testing strategy
347 ensures the fidelity of HIV diagnosis and subsequent care and treatment, the main determinant
348 of HIV testing programme cost is the overall scale of HIV testing and the number A1 conducted.

349 **References**

- 350 1. Global programme on AIDS. Recommendations for the selection and use of HIV antibody
351 tests. *Wkly Epidemiol Rec Relev Epidemiol Hebd World Heal Organ.* 1992;67: 145–149.
- 352 2. Joint United Nations Programme on HIV/AIDS (UNAIDS)-WHO. Revised
353 recommendations for the selection and use of HIV antibody tests. *Wkly Epidemiol Rec.*
354 1997;72: 81–7. Available: <http://www.ncbi.nlm.nih.gov/pubmed/9238418>
- 355 3. World Health Organization. Selecting and purchasing HIV, HBsAg and HCV in vitro
356 diagnostics. 2021 [cited 23 Feb 2021]. Available:
357 https://www.who.int/diagnostics_laboratory/procurement/purchase/en/
- 358 4. World Health Organization. Consolidated guidelines on HIV testing services. 2015 p. 193.
359 Available: http://apps.who.int/iris/bitstream/10665/179870/1/9789241508926_eng.pdf
- 360 5. Giguère K, Eaton JW, Marsh K, Johnson LF, Johnson CC, Ehui E, et al. Trends in
361 knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa,
362 2000–20: a modelling study using survey and HIV testing programme data. *Lancet HIV.*
363 2021 [cited 8 Mar 2021]. doi:10.1016/S2352-3018(20)30315-5
- 364 6. Fonner VA, Sands A, Figueroa C, Baggaley R, Quinn C, Jamil MS, et al. Country
365 adherence to WHO recommendations to improve the quality of HIV diagnosis: a global
366 policy review. *BMJ Glob Heal.* 2020;5: e001939. doi:10.1136/bmjgh-2019-001939
- 367 7. World Health Organization. Consolidated guidelines on HIV testing services 2019. 2019
368 [cited 23 Feb 2021] p. 261. Available:
369 <https://apps.who.int/iris/rest/bitstreams/1313903/retrieve>
- 370 8. WHO Prequalifications Team: Diagnostics. Technical specification series for submission

- 371 to WHO prequalification – Diagnostic Assessment: TSS-1: Human Immunodeficiency
372 Virus (HIV) rapid diagnostic tests for professional and/or self-testing. 2016 [cited 15 Nov
373 2018]. Available: [http://apps.who.int/iris/bitstream/handle/10665/251857/9789241511742-](http://apps.who.int/iris/bitstream/handle/10665/251857/9789241511742-eng.pdf)
374 [eng.pdf](http://apps.who.int/iris/bitstream/handle/10665/251857/9789241511742-eng.pdf)
- 375 9. World Health Organization. Global Price Reporting Mechanism. 2017 [cited 10 Dec 2017].
376 Available: <https://apps.who.int/hiv/amds/price/hdd>
- 377 10. Government of Malawi Ministry of Health. Integrated HIV Program Report October-
378 December 2017. Lilongwe; 2018.
- 379 11. Stover J, Glaubius R, Mofenson L, Dugdale CM, Davies MA, Patten G, et al. Updates to
380 the Spectrum/AIM model for estimating key HIV indicators at national and subnational
381 levels. *AIDS*. 2019;33: S227–S234. doi:10.1097/QAD.0000000000002357
- 382 12. Eaton JW, Brown T, Puckett R, Glaubius R, Mutai K, Bao L, et al. The Estimation and
383 Projection Package Age-Sex Model and the r-hybrid model: new tools for estimating HIV
384 incidence trends in sub-Saharan Africa. *AIDS*. 2019;33 Suppl 3: S235–S244.
385 doi:10.1097/QAD.0000000000002437
- 386 13. Maheu-Giroux M, Marsh K, Doyle CM, Godin A, Lanière Delaunay C, Johnson LF, et al.
387 National HIV testing and diagnosis coverage in sub-Saharan Africa. *AIDS*. 2019;33:
388 S255–S269. doi:10.1097/QAD.0000000000002386
- 389 14. Eaton JW, Johnson CC, Gregson S. The Cost of Not Retesting: Human
390 Immunodeficiency Virus Misdiagnosis in the Antiretroviral Therapy “Test-and-Offer” Era.
391 *Clin Infect Dis*. 2017;65. doi:10.1093/cid/cix341
- 392 15. Lasry A, Kalou MB, Young PR, Rurangirwa J, Parekh B, Behel S. Cost implications of

- 393 HIV retesting for verification in Africa. PLoS One. 2019;14.
394 doi:10.1371/journal.pone.0218936
- 395 16. Bhattacharya R, Barton S, Catalan J. When good news is bad news: Psychological
396 impact of false positive diagnosis of HIV. AIDS Care - Psychol Socio-Medical Asp
397 AIDS/HIV. 2008;20: 560–564. doi:10.1080/09540120701867206
- 398 17. Johnson CC, Dalal S, Baggaley R, Taegtmeyer M. A public health approach to
399 addressing and preventing misdiagnosis in the scale-up of HIV rapid testing programmes.
400 Journal of the International AIDS Society. International AIDS Society; 2017.
401 doi:10.7448/IAS.20.7.22190
- 402

403 **Table 1.** HIV testing strategy outcomes per 100,000 tested for 10%, 5%, 1%, and 0.5% true
 404 positivity among clients presenting for HIV testing
 405

	10% positivity			5% positivity		
	2-test	3-test	WHO 2019	2-test	3-test	WHO 2019
HIV-negative classifications	90,022	90,049	89,712	94,968	94,985	94640
HIV-positive classifications	9922	9781	9704	4985	4891	4852
HIV-inconclusive	55	170	584	47	124	508
Observed positivity	9.93%	9.80%	9.76%	4.99%	4.90%	4.88%
False HIV-positive	43.1	0.86	0.72	45.4	0.91	0.76
False HIV-negative	100.4	119.8	101.0	50.2	59.9	50.5
PPV of entire testing strategy	99.6%	>99.9%	>99.9%	99.1%	>99.9%	>99.9%
NPV of entire testing strategy	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%
Assay 1 used	101,918	102,033	102,447	101,959	102,036	102,419
Assay 2 used	13,583	13,663	11,896	8,772	8,811	6,948
Assay 3 used	365	10,022	10,033	375	5,035	5,037
Cost (US\$)	\$385,143	\$409,869	\$407,282	\$374,144	\$386,155	\$383,216

	1% positivity			0.5% positivity		
	2-test	3-test	WHO 2019	2-test	3-test	WHO 2019
HIV-negative classifications	98,924	98,934	98582	99,419	99,427	99075
HIV-positive classifications	1035	979	971	542	490	486
HIV-inconclusive	41	87	446	40	83	439
Observed positivity	1.04%	0.98%	0.98%	0.54%	0.49%	0.49%
False HIV-positive	47.4	0.95	0.79	47.60	0.95	0.80
False HIV-negative	10.0	12.0	10.1	5.0	6.0	5.0
PPV of entire testing strategy	95.4%	99.9%	99.9%	91.2%	99.8%	99.8%
NPV of entire testing strategy	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%
Assay 1 used	101,991	102,038	102,397	101,995	102,038	102,394
Assay 2 used	4,922	4,930	2,990	4,441	4,445	2,495
Assay 3 used	382	1,045	1,039	383	547	540
Cost (US\$)	\$365,345	\$367,184	\$363,963	\$364,245	\$364,813	\$361,556


406 **NPV:** negative predictive value; **PPV:** positive predictive value. **Note:** 2-test and 3-test denotes the number of
 407 consecutive HIV reactive tests to provide an HIV-positive diagnosis under the WHO 2015 guidelines 'high prevalence'
 408 and 'low prevalence' strategies, respectively, not number of tests required by the strategy. Specimens with repeated
 409 discrepant test results under the 2-test strategy proceed to a third assay. Specimens with repeat discrepant test
 410 results on the first two tests are ruled negative. In the 'WHO 2019' testing strategy, only A1 is repeated.

411 **Table 2.** True HIV status for persons classified as ‘HIV-inconclusive’ under the WHO 2019 HIV
 412 testing strategy. All results per 100,000 persons tested.

413


	Testing Strategy Result Given			Positivity			
	2-test	3-test	WHO 2019	10%	5%	1%	0.5%
Total inconclusive				584	508	446	439
True HIV-negative				388 (66%)	410 (81%)	427 (96%)	429 (98%)
True HIV-positive				196 (34%)	98 (19%)	20 (4%)	10 (2%)
Total A1+ / A2- / A1+				451	421	398	395
True HIV-negative	Rep. A2	Rep. A2	INC	353 (78%)	372 (88%)	388 (98%)	390 (99%)
True HIV-positive	Rep. A2	Rep. A2	INC	98 (22%)	49 (12%)	10 (2%)	5 (1%)
Total A1+ / A2+ / A3-				133	86	49	44
True HIV-negative	False pos.	INC	INC	35 (26%)	37 (43%)	39 (80%)	39 (89%)
True HIV-positive	Corr. pos.	INC	INC	98 (74%)	49 (57%)	10 (20%)	5 (11%)

414 **Rep. A2** = Under the WHO 2015 HIV testing strategies (2-test and 3-test), the A2 test is repeated.; **INC** =
 415 Inconclusive HIV test result returned with instruction to return after 14 days for retesting.; **False pos.** = A false
 416 positive HIV diagnosis is returned under the WHO 2015 2-test strategy; **Corr. pos.** = A correct HIV positive diagnosis
 417 is returned under the WHO 2015 2-test strategy.




419

420 **Figure 1.** HIV testing strategies modelled. (A) and (B) are redrawn following *WHO Consolidated Guidelines on HIV*
 421 *Testing Services 2015* Figures 7.2 and 7.3 [4]. (A) and (B) assume a 3rd generation A1 assay is used. (C) is redrawn
 422 following *WHO Consolidated Guidelines on HIV Testing Services 2019* Figure 8.3 [7].




423

424 **Figure 2.** (A) Expected number of false negative, false positive, and inconclusive classifications
425 per 100,000 clients tested under alternative testing strategies for true prevalence among HIV
426 testing clients ranging from 20% to 0.2%. (B) Negative predictive value (NPV) and positive
427 predictive value (PPV) for alternative testing strategies for prevalence ranging from 20% to
428 0.2%. Black dashed line indicates WHO target of 99% PPV and 99% NPV for HIV testing
429 strategies.




430

431 **Figure 3.** (A) Expected number of tests used by assay per 100,000 tested under the 2-test, 3-
432 test, and WHO 2019 testing strategies for positivity ranging from 20% to 0.2%. (B) Estimated
433 cost per 100,000 tested as a function of HIV positivity for each strategy. (C) Ratio of total cost
434 under the WHO 2019 testing strategy versus the WHO 2015 2-test (high prevalence) strategy.



435

436 **Figure 4.** Estimates and projections for the HIV population and HIV testing programme in
 437 Malawi over period 2000 to 2025. (A) Total number of adult (15+ years) PLHIV stratified by
 438 undiagnosed, aware of HIV status but untreated, and on ART. (B) Total number of HIV tests per
 439 year amongst adults age 15+ and number of HIV-positive diagnoses. (C) HIV prevalence (light
 440 red shaded area) and prevalence of undiagnosed HIV (dark red) in the adult population (15+
 441 years), and HIV positivity amongst those tested for HIV (solid line) and the 'yield' of new
 442 diagnoses (dotted line). 'Positivity' reflects the proportion of HTS clients who are positive
 443 including both new diagnoses and those re-testing who are already aware or on ART. 'Yield' of
 444 new diagnoses reflects the estimated proportion of HTS clients who being diagnosed for the first
 445 time. (Source: Malawi 2020 UNAIDS Spectrum Estimates.)



446
447 **Figure 5.** (A) Predicted negative predictive value (NPV) and positive predictive value (PPV) for
448 adults presenting to HIV testing in Malawi over period 2000 to 2025 using the WHO 2015 '2-test'
449 (high prevalence) strategy compared to the WHO 2019 recommended strategy and assuming
450 each assay performs at the minimum level required for WHO prequalification (99% sensitivity,
451 98% specificity). (B) Expected number of tests used by the WHO 2019 strategy. (C) Ratio of
452 total cost per year for implementing the WHO 2019 strategy compared to the 2-test strategy.
453 Dotted vertical line denotes year 2019 reflecting the final year of HIV testing programme data
454 incorporated in estimates. Results for 2020 through 2025 reflect projections assuming HIV
455 testing rates for 2019 continue through 2025.